Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment
Authors:
- Hans OrlentHOHans Orlent
- Isabelle DesombereIDIsabelle Desombere
- Bettina HansenBHBettina Hansen
- Hans Van VlierbergheHVHans Van Vlierberghe
- Bart HaagmansBHBart Haagmans
- Robert J. De KnegtRKRobert J. De Knegt
- Solko W. SchalmSSSolko W. Schalm
- Geert Leroux-RoelsGLGeert Leroux-Roels
- Harry L.A. JanssenHJHarry L.A. Janssen
- 1 September 2010
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 22 (12) , 1443-8
Abstract
Early detection of nonresponders to hepatitis C therapy limits unnecessary exposure to treatment and its side-effects. A recent algorithm combining baseline anti-NS4a antibodies and on-treatment quantitative PCR identified nonresponders to a combination of interferon and ribavirin after 1 week of treatment. To validate a stopping rule based on baseline anti-NS4a antibody levels and early on-treatment virological response in treatment-naive genotype 1 chronic hepatitis C patients treated with the current standard pegylated interferon and ribavirin combination therapy. Eighty-nine genotype 1 patients from the Dynamically Individualized Treatment of hepatitis C Infection and Correlates of Viral/Host dynamics Study treated for 48 weeks with standard 180 μg pegylated interferon (PEG-IFN)-α-2a (weekly) and ribavirin 1000-1200 mg (daily) were analysed. Baseline anti-NS4a antibody enzyme-linked immunosorbent assay (NS4a AA 1687-1718) was performed on pretreatment serum. Hepatitis C virus-RNA was assessed at days 0, 1, 4, 7, 8, 15, 22, 29, weeks 6, 7, 8, 10, 12 and 6 weekly thereafter until end of treatment. Multiple regression logistic analysis was performed. Overall 54 of 89 (61%) patients achieved sustained virological response. A baseline anti-NS4a antibody titre less than 1/1250 correlated with absence of favourable initial viral decline according to variable response types (P = 0.015). The optimal algorithm was developed using the combination of the absence of anti-NS4a Ab (<1/1250) at baseline and the presence of a viral load ≥ 100.000 IU/ml at week 4. This algorithm has a specificity of 43% and negative predictive value of 100% to detect nonresponse to standard PEG-IFN-α-2a and ribavirin therapy at fourth week of therapy (intention-to-treat analysis). The decision to stop the therapy in genotype 1 chronic hepatitis C patients treated with PEG-IFN-α-2a and ribavirin can be confidently made after 4 weeks of treatment based on the absence of baseline anti-NS4a Ab and a week-4 hepatitis C virus-RNA above 100.000 IU/ml.Keywords
This publication has 18 references indexed in Scilit:
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Treatment predictors of a sustained virologic response in hepatitis B and CJournal of Hepatology, 2008
- Interferon signaling and treatment outcome in chronic hepatitis CProceedings of the National Academy of Sciences, 2008
- Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis CJournal of Medical Virology, 2007
- Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunityProceedings of the National Academy of Sciences, 2005
- Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virusNature, 2005
- International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis CJournal of Hepatology, 2005
- Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIFProceedings of the National Academy of Sciences, 2005
- Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)Journal of Hepatology, 2002
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002